Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Jennifer W. Leiding, Danielle E. Arnold, Suhag Parikh, Brent Logan, Rebecca A. Marsh, Linda M. Griffith, Ruizhe Wu, Sharon Kidd, Kanwaldeep Mallhi, Deepak Chellapandian, Stephanie J. Si Lim, Eyal Grunebaum, E. Liana Falcone, Luis Murguia-Favela, Debbi Grossman, Vinod K. Prasad, Jennifer R. Heimall, Fabien Touzot, Lauri M. Burroughs, Jack Bleesing, Neena Kapoor, Jasmeen Dara, Olatundun Williams, Malika Kapadia, Benjamin R. Oshrine, Jeffrey J. Bednarski, Ahmad Rayes, Hey Chong, Geoffrey D. E. Cuvelier, Lisa R. Forbes Satter, Caridad Martinez, Mark T. Vander Lugt, Lolie C. Yu, Shanmuganathan Chandrakasan, Avni Joshi, Susan E. Prockop, Blachy J. Dávila Saldaña, Victor Aquino, Larisa A. Broglie, Christen L. Ebens, Lisa M. Madden, Kenneth DeSantes, Jordan Milner, Hemalatha G. Rangarajan, Ami J. Shah, Alfred P. Gillio, Alan P. Knutsen, Holly K. Miller, Theodore B. Moore, Pamela Graham, Andrea Bauchat, Nancy J. Bunin, Pierre Teira, Aleksandra Petrovic, Sharat Chandra, Hisham Abdel-Azim, Morna J. Dorsey, Olga Birbrayer, Morton J. Cowan, Christopher C. Dvorak, Elie Haddad, Donald B. Kohn, Luigi D. Notarangelo, Sung-Yun Pai, Jennifer M. Puck, Michael A. Pulsipher, Troy R. Torgerson, Harry L. Malech, Elizabeth M. Kang

Blood (2023) 142 (24): 2105–2118.

https://doi.org/10.1182/blood.2022019586

Published: 2023

Includes: Supplemental data

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Elizabeth Stenger, Tami D. John, Deepak Chellapandian, Rikin Shah, Scott Gillespie, Yijin Xiang, Katie Liu, Monica Bhatia, Gregory M.T. Guilcher, Jennifer Jaroscak, Kimberly A. Kasow, Jennifer Krajewski, Alexander I. Ngwube, Hemalatha G. Rangarajan, John T. Horan, Lakshmanan Krishnamurti, Shalini Shenoy, Allistair Abraham

Blood (2023) 142 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2023-188514

Published: 2023

Journal Articles

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Blood (2023) 142 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2023-182532

Published: 2023

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

Granulocyte Transfusions in Children Undergoing Hematopoietic Stem Cell Transplantation

Lisa Hall, Veronika Polishchuk, Hemalatha G. Rangarajan, Rolla Abu-Arja, Kathleen Nicol, Rajinder Bajwa

Blood (2022) 140 (Supplement 1): 12837.

https://doi.org/10.1182/blood-2022-170130

Published: 2022

Journal Articles

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 10462–10464.

https://doi.org/10.1182/blood-2022-170552

Published: 2022

Journal Articles

Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E. Lehmann, Hemalatha G. Rangarajan, Jaime M. Preussler, Jesse D. Troy, Luke P. Akard, Neel S. Bhatt, Tony H. Truong, William A. Wood, Jr., Douglas Rizzo, Wael Saber

Blood (2022) 140 (Supplement 1): 10845–10846.

https://doi.org/10.1182/blood-2022-163451

Published: 2022

Journal Articles

Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?

Karen K. Ballen, Tao Wang, Naya He, Shahrukh Hashmi, Leslie E. Lehmann, William A. Wood, Jr., Hemalatha G. Rangarajan, Wael Saber

Blood (2022) 140 (Supplement 1): 685–686.

https://doi.org/10.1182/blood-2022-159152

Published: 2022

Journal Articles

International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens

Blood (2022) 140 (Supplement 1): 4711–4713.

https://doi.org/10.1182/blood-2022-160305

Published: 2022

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 2383–2385.

https://doi.org/10.1182/blood-2022-165229

Published: 2022

Journal Articles

CAR-T Prescriber Preferences in Adolescents and Young Adults with B-ALL

Richard Curtis Godby, Asmaa Ferdjallah, Hassan B. Alkhateeb, Victor Aquino, Michelle P. Hudspeth, Hemalatha G. Rangarajan, Carrie Lynn Kitko, Eric Jon Anderson, Susan Kelly, Arunkumar J. Modi, Emmanuel Katsanis, Shanti Ramachandran, Yi Lin, Mira A Kohorst

Blood (2022) 140 (Supplement 1): 12762–12763.

https://doi.org/10.1182/blood-2022-163390

Published: 2022

Journal Articles

Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial

Robert Sheppard Nickel, KY Chiang, Steven J. Hardy, Hemalatha G Rangarajan, Sonali Chaudhury, Michael Kent, Monica Bhatia, Jeremy Zack, Vivitha Mani, Gregory M.T. Guilcher, Allistair Abraham

Blood (2021) 138 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2021-144454

Published: 2021

Journal Articles

Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Hemalatha G Rangarajan, MD, Marcelo De Souza Pereira, Ruta Brazauskas, PhD, Michael R Verneris, MD, Andrew St. Martin, MS, Stephen R. Spellman, MS, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139891

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC)

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139958

Published: 2020

Journal Articles

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Michael R Verneris, MD, Tao Wang, PhD, Stephen R. Spellman, Jennifer A. Sees, MPH, Michael D. Haagenson, MS, Sarah Cooley, MD, Katharine C. Hsu, MD PhD, Katharina Fleischhauer, Katharina Fleischhauer, Dean Anthony Lee, MD PhD, Sophie Paczesny, MD PhD, Hemalatha G. Rangarajan, MD, Jeffrey S. Miller, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2018-99-116428

Published: 2018

Journal Articles

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Allistair Abraham, MD, Elizabeth Stenger, MD, Curtis D Travers, MPH, Robert Nickel, MDMSc, Hemalatha G. Rangarajan, MD, Jennifer Krajewski, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Troy C. Quigg, DO, Alexander I. Ngwube, MD, Jennifer Jaroscak, MD, Gregory M Guilcher, MDBSc,FRCPC, Shalini Shenoy, MD, John T Horan, MD

Blood (2017) 130 (Supplement 1): 3535.

https://doi.org/10.1182/blood.V130.Suppl_1.3535.3535

Published: 2017

Journal Articles

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Elizabeth Stenger, MD, Allistair Abraham, MD, Curtis D Travers, MPH, Hemalatha G. Rangarajan, MD, Diane Hsu, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Michael J. Eckrich, MD MPH, Alexander I. Ngwube, MD, Julie Kanter, MD, Gregory M Guilcher, MDBSc,FRCPC, John T. Horan, MDMPH, Lakshmanan Krishnamurti, MD, Shalini Shenoy, MD

Blood (2017) 130 (Supplement 1): 3271.

https://doi.org/10.1182/blood.V130.Suppl_1.3271.3271

Published: 2017

NARROW

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Granulocyte Transfusions in Children Undergoing Hematopoietic Stem Cell Transplantation

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?

International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

CAR-T Prescriber Preferences in Adolescents and Young Adults with B-ALL

Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial

Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC)

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only